The #FDA has started a review of the #marketingapplication for #Takeda's #TYK2inhibitor zasocitinib in #psoriasis, setting up a decision in mid-March 2027.
pharmaphorum.com/news/fda-dec...
pharmaphorum.com/news/fda-dec...
FDA to decide on Takeda's psoriasis blockbuster hope in Q1
The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.
pharmaphorum.com
September 15, 2026 at 10:24 AM
The #FDA has started a review of the #marketingapplication for #Takeda's #TYK2inhibitor zasocitinib in #psoriasis, setting up a decision in mid-March 2027.
pharmaphorum.com/news/fda-dec...
pharmaphorum.com/news/fda-dec...
#Alumis is preparing to file its oral #TYK2inhibitor envudeucitinib as a treatment for #psoriasis later this year, after a pair of positive phase 3 trials.
Alumis shoots up as its Sotyktu rival aces psoriasis trials
Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.
buff.ly
January 6, 2026 at 4:30 PM
#Alumis is preparing to file its oral #TYK2inhibitor envudeucitinib as a treatment for #psoriasis later this year, after a pair of positive phase 3 trials.